{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+10%25&page=2",
    "query": {
      "intervention": "Dextrose 10%",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dextrose+10%25&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T02:09:55.807Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01301053",
      "title": "Pilot Study of Intensive Care Unit Continuous Glucose Monitoring",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperglycemia",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Current UVA intensive care insulin protocol",
          "type": "OTHER"
        },
        {
          "name": "Current UVA intensive care insulin protocol with \"brakes\"",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-02",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301053"
    },
    {
      "nct_id": "NCT00546728",
      "title": "The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Paul Heart Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2013-11-08",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 2,
      "location_summary": "Saint Louis Park, Minnesota • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546728"
    },
    {
      "nct_id": "NCT01681095",
      "title": "Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Myocardial Ischemia",
        "Coronary Disease",
        "Heart Diseases",
        "Valvular Heart Disease"
      ],
      "interventions": [
        {
          "name": "Custodiol HTK",
          "type": "DRUG"
        },
        {
          "name": "Cold Blood Cardioplegia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marc Sakwa, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2012-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681095"
    },
    {
      "nct_id": "NCT05025735",
      "title": "Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10Mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saint Luke's Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2021-08-25",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025735"
    },
    {
      "nct_id": "NCT04893226",
      "title": "Circadian Rhythms in Postmenopausal Women",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Postmenopausal Symptoms"
      ],
      "interventions": [
        {
          "name": "Time-Restricted Feeding (TRF)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Julie Pendergast",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 65 Years · Female only"
      },
      "enrollment_count": 164,
      "start_date": "2021-10-19",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04893226"
    },
    {
      "nct_id": "NCT03120585",
      "title": "Fluid Restriction in Respiratory Distress of the Newborn",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Newborn"
      ],
      "interventions": [
        {
          "name": "Fluid Management Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Hours",
        "sex": "ALL",
        "summary": "Up to 12 Hours"
      },
      "enrollment_count": 65,
      "start_date": "2017-03-01",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-06-30",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 2,
      "location_summary": "New York, New York • Lawton, Oklahoma",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Lawton",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03120585"
    },
    {
      "nct_id": "NCT04383314",
      "title": "Targeting Hyaluronan Accumulation Through Exercise in T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "10-week exercise program on HA accumulation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-01",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-31",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04383314"
    },
    {
      "nct_id": "NCT06638099",
      "title": "Increasing CGM Use Among Patients With T2D",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus",
        "Diabetes Mellitus Type 2",
        "Diabetes Mellitus Type 2 (T2DM)"
      ],
      "interventions": [
        {
          "name": "CGM Toolkit Prescriber Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "San Diego State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 195,
      "start_date": "2024-11-04",
      "completion_date": "2026-06-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 2,
      "location_summary": "El Centro, California",
      "locations": [
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06638099"
    },
    {
      "nct_id": "NCT04595370",
      "title": "Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "AZD9977",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "21 Years to 130 Years"
      },
      "enrollment_count": 153,
      "start_date": "2021-01-26",
      "completion_date": "2023-09-22",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 26,
      "location_summary": "Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "South Gate",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04595370"
    },
    {
      "nct_id": "NCT04607668",
      "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Cancer Metastatic",
        "Myelosuppression-Adult",
        "Chemotherapeutic Toxicity"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "G1 Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2021-01-06",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-09-25T02:09:55.807Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04607668"
    }
  ]
}